Related references
Note: Only part of the references are listed.HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b
Yosuke Hirotsu et al.
HEPATOLOGY INTERNATIONAL (2015)
Interactions of the Hepatitis C Virus Protease Inhibitor Faldaprevir With Cytochrome P450 Enzymes: In Vitro and In Vivo Correlation
John P. Sabo et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
Peter Ferenci et al.
JOURNAL OF HEPATOLOGY (2015)
Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis
Stefan Zeuzem et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
Stefan Zeuzem et al.
LIVER INTERNATIONAL (2015)
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
Shuhei Nishiguchi et al.
LIVER INTERNATIONAL (2014)
The elusive function of the hepatitis C virus p7 protein
Ali M. Atoom et al.
VIROLOGY (2014)
Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
Tatsuo Kanda et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2014)
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial
Mark S. Sulkowski et al.
HEPATOLOGY (2013)
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
Mark S. Sulkowski et al.
HEPATOLOGY (2013)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2013)
Faldaprevir and Deleobuvir for HCV Genotype 1 Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
Shuang Wu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335
Lisette Lagace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
APASL consensus statements and management algorithms for hepatitis C virus infection
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2012)
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
Stefan Zeuzem et al.
GASTROENTEROLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
Michael P. Manns et al.
JOURNAL OF HEPATOLOGY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Progress Toward Development of a Hepatitis C Vaccine with Broad Shoulders
Ranjit Ray
SCIENCE TRANSLATIONAL MEDICINE (2011)
Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease
Peter W. White et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
New antiviral therapies for chronic hepatitis C
Tatsuo Kanda et al.
HEPATOLOGY INTERNATIONAL (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
Thomas Vanwolleghem et al.
GASTROENTEROLOGY (2007)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
Share Paper
